In addition, a phase III RCT IMpower-150 found that in a subset of EGFR/ALK-positive advanced NS-NSCLC patients whose disease progressed on prior targeted therapy, adding atezolizumab to PC + B can significantly improve the survival. Here, EGFR is linked to non-small cell lung carcinoma.